Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Cytotoxic lymphocyte antigen-4 (CTLA-4) blockade is an active immunotherapeutic strategy that is currently in clinical trials in cancer. There are several ongoing trials of anti-CTLA-4 in the metastatic setting of prostate cancer patients with reported clinical responses consisting of decreases in the prostate specific antigen (PSA) tumor marker for some patients. Immunologic markers that correlate with these clinical responses are necessary to guide further development of anti-CTLA-4 therapy in the treatment of cancer patients. We recently reported that CD4(+) inducible co-stimulator (ICOS)(hi) T cells that produce interferon-gamma (IFN-gamma) are increased in the peripheral blood and tumor tissues of bladder cancer patients treated with anti-CTLA-4 antibody. Here we present data from the same clinical trial in bladder cancer patients demonstrating a higher frequency of CD4(+)ICOS(hi) T cells and IFN-gamma mRNA levels in nonmalignant prostate tissues and incidental prostate tumor tissues removed at the time of radical cystoprostatectomy. Our data suggest immunologic markers that can be used to monitor prostate cancer patients who receive anti-CTLA-4 therapy and indicate that the immunologic impact of anti-CTLA-4 antibody can occur in both tumor and nonmalignant tissues. These data should be taken into consideration for evaluation of efficacy as well as immune-related adverse events associated with anti-CTLA-4 therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anti-CTLA4 predominantly affects CD4 T cells, with multiple studies identifying increased frequency of a Th1 subset of CD4 T cells that express inducible costimulator (ICOS) as a result of anti-CTLA4 therapy (17)(18)(19).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [19]
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187 · cited 1×
“However, the frequency of CD4 FOXP3 regulatory T cells (17), was considerably higher in the peripheral blood of prostate cancer patients than in healthy donors (43% vs.”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“Blockade of the inhibitory signals mediated by CTLA-4 has been shown to enhance T cell responses and induce tumor rejection in a number of animal models (4, 5).”
BackgroundA Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589 · cited 1×
“Both prostate cancer and nonmalignant tissues had higher mRNA levels for IFN- , a Th1 cytokine (26), and T-bet, a transcription factor responsible for regulating IFN- production (27), as compared to untreated tissues.”
BackgroundZheng, W.-P., & Flavell, R. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80240-8 · Cited by 2,384
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The lineage decisions of helper T cells
Murphy, K. M., & Reiner, S. L. (2002) · Nature Reviews Immunology · doi:10.1038/nri954 · Cited by 1,674
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617 · cited 1×
“Both prostate cancer and nonmalignant tissues had higher mRNA levels for IFN- , a Th1 cytokine (26), and T-bet, a transcription factor responsible for regulating IFN- production (27), as compared to untreated tissues.”
BackgroundPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Hori, S., Nomura, T., & Sakaguchi, S. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.981 · Cited by 1,066
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012 · cited 1×
“Published studies suggest that irAEs and clinical benefit occur in the same patients (11).”
BackgroundHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
ICOS co-stimulatory receptor is essential for T-cell activation and function
Dong, C., Juedes, A. E., Temann, U.-A., Shresta, S., Allison, J. P., Ruddle, N. H., & Flavell, R. A. (2001) · Nature · doi:10.1038/35051100 · Cited by 936
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
T-cell co-stimulation through B7RP-1 and ICOS
Yoshinaga, S. K., Whoriskey, J. S., Khare, S. D., Sarmiento, U., Guo, J., Horan, T., Shih, G., Zhang, M., Coccia, M. A., Kohno, T., et al. (1999) · Nature · doi:10.1038/45582 · Cited by 777
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 2×
“Sensitized CD4 T cells were then tested with target APCs without peptide or pulsed with peptide in ELISPOT assays as previously described (30).”
BackgroundMethodWoo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 696
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · cited 4×
“In a previous report it was shown that anti-CTLA-4 therapy led to the development of skin rash in a subset of melanoma patients and biopsies from these nonmalignant areas revealed CD4 and CD8 T cell infiltrates (32).”
BackgroundInfluentialLiakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549
Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F., Reuter, V. E., Herr, H., Old, L. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611618104 · Cited by 526 · cited 1×
“Conversely, increased intratumoral effector T cells and higher ratios of effector to regulatory T cells in tumor tissues have been associated with improved clinical outcome (24, 25).”
BackgroundSelf-citationThe CD28-Related Molecule ICOS Is Required for Effective T Cell–Dependent Immune Responses
Coyle, A. J., Lehar, S., Lloyd, C., Tian, J., Delaney, T., Manning, S., Nguyen, T., Burwell, T., Schneider, H., Gonzalo, J. A., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00011-x · Cited by 520
Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., & Fujii, H. (2003) · PubMed · Cited by 489
CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients
Miller, A. M., Lundberg, K., Özenci, V., Banham, A. H., Hellström, M., Egevad, L., & Pisa, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7398 · Cited by 421
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407 · cited 1×
“Prostate cancer patients have been reported to have decreases in the prostate-specific antigen (PSA) tumor marker after treatment with anti-CTLA-4 antibody (10).”
BackgroundYuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810114105 · Cited by 348
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
Jungbluth, A. A., Chen, Y.-T., Stockert, E., Busam, K. J., Kolb, D., Iversen, K., Coplan, K., Williamson, B., Altorki, N., & Old, L. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1282 · Cited by 347
Clark, R. A., Huang, S. J., Murphy, G. F., Mollet, I. G., Hijnen, D., Muthukuru, M., Schanbacher, C. F., Edwards, V., Miller, D. M., Kim, J. E., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071190 · Cited by 243
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Saenger, Y. M., & Wolchok, J. D. (2008) · PubMed · Cited by 165
Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D. J., Wunderlich, J. R., Merino, M. J., & Rosenberg, S. A. (2008) · Blood · doi:10.1182/blood-2008-06-163048 · Cited by 141
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (2011) · The Journal of Immunology · doi:10.1093/ji/187.7.3466 · Cited by 100
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman, A. J., Yellin, M. J., & Keler, T. (2005) · PubMed · Cited by 85
NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Gnjatic, S., Altorki, N. K., Tang, D. N., Tu, S.-M., Kundra, V., Ritter, G., Old, L. J., Logothetis, C. J., & Sharma, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2632 · Cited by 79 · cited 2×
“Immunohistochemical staining was done for NYESO-1 and CD4 using monoclonal antibodies E978 as previously described (34) and 1F6 (Labvision), respectively.”
BackgroundMethodSun, J., Schiffman, J. S., Raghunath, A., Tang, D. N., Chen, H., & Sharma, P. (2008) · PubMed Central · Cited by 41
Cited by
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
“…associated with –CTLA-4–mediated tumor rejection is an increase in the ratio of T eff to T reg cells within the tumor (T eff/T reg cell ratio; Shrikant et al., 1999; Quezada et al., 2006; Kavanagh et al., 2008; Liakou et al., 2008; Chen et al., 2009; Curran and Allison, 2009; Waitz et al., 2012).”
BackgroundLoss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Self-citation
Metadata
- Authors
- Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., & Sharma, P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Urology,
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-02-24
- Volume
- 106
- Issue
- 8
- Pages
- 2729-2734
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2650334
- OpenAlex
- W2155101465
- Cited by
- 218
- References
- 37
- Citations by year
- 2026: 3 · 2025: 14 · 2024: 16 · 2023: 8 · 2022: 12 · 2021: 23 · 2020: 12 · 2019: 12 · 2018: 19 · 2017: 15 · 2016: 16 · 2015: 10 · 2014: 6 · 2013: 13 · 2012: 14
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Prostate Cancer Foundation
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CD4+ T cells, ICOS, interferon-gamma, prostate cancer, bladder cancer, tumor-infiltrating lymphocytes, immunological markers, immune-related adverse events, radical cystoprostatectomy
- MeSH terms
- Antibodies, Humans, Interferon-gamma, Male, Prostate, Prostatic Neoplasms, RNA, Messenger, CD4-Positive T-Lymphocytes, Antigens, CD, Lymphocytes, Tumor-Infiltrating, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.